Please assess the completion status of the following clinical trial:

Trial Title: Bioavailability of Subcutaneous Dexmedetomidine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fluent skills in the Finnish language in order to be able to give informed consent and communicate with the study personnel.~* Age ≥ 18 years.~* Male gender.~* Weight ≥ 60 kg.~* Written informed consent from the subject.~Exclusion Criteria:~* Previous history of intolerance to the study drug or related compounds and additives.~* Concomitant drug therapy of any kind except paracetamol in the 14 days prior to the study.~* Existing or recent significant disease.~* History of any kind of drug allergy.~* Previous or present alcoholism, drug abuse, psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements.~* Donation of blood within six weeks prior to and during the study.~* Body weight \< 60 kg or BMI \> 30 kg / m2.~* Participation in any other clinical study involving investigational or marketed drug products concomitantly or within one month prior to the entry into this study.~* Smoking during one month before the start of the study or during the study period.~* Clinically significant abnormal findings in physical examination, ECG or laboratory screening

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- intravenous (Type: ACTIVE_COMPARATOR): 1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously in 10 min at a constant rate using an infusion pump.
- subcutaneous (Type: ACTIVE_COMPARATOR): 1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) will be administered subcutaneously undiluted.

Based on this trial design, predict the completion outcome and termination type (if applicable).